Table 1.
Characteristics of study participants in the CONVERT trial and in the time to positivity secondary analysis
| Characteristic | Intention-to-treat analysis population in CONVERT trial (N = 336) |
At least one screening time to positivity value (N = 71) |
|---|---|---|
| Age in years, mean (SD) | 64.7 (9.77) | 65.6 (8.62) |
| Race: white, n (%) | 235 (69.9) | 62 (87.3) |
| Sex: female, n (%) | 233 (69.3) | 45 (63.4) |
| Baseline body mass index (kg/m2), mean (SD) | 21.17 (3.875) | 21.23 (3.870) |
| Tobacco use: current smoker, n (%) | 36 (10.7) | 13 (18.3) |
| Lung disease, n (%) | ||
| COPD | 48 (14.3) | 24 (33.8) |
| Bronchiectasis | 211 (62.8) | 26 (36.6) |
| COPD and bronchiectasis | 40 (11.9) | 11 (15.5) |
| Duration of NTM disease in years, mean (SD) | 5.7 (5.07) | 4.9 (4.95) |
| Duration of NTM treatment prior to study enrollment in years, mean (SD) | 3.9 (3.9) | 3.9 (4.0) |
| Assigned treatment in CONVERT trial | ||
| ALIS plus guideline-based therapy, n (%) | 224 (66.7) | 43 (60.6) |
| Guideline-based therapy only, n (%) | 112 (33.3) | 28 (39.4) |
| Conversion of sputum cultures to negative by month 6, n (%) | 75 (22.3) | 10 (14.1) |
SD, standard deviation; COPD, chronic obstructive pulmonary disease; NTM, nontuberculous mycobacterial disease; ALIS, amikacin liposomal inhalation suspension